Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:

Ascletis Says PD-L1 Induces “Functional Cure” in CHB Patients

publication date: Jul 1, 2022

Hangzhou Ascletis Pharma reported that chronic hepatitis B patients experienced a “functional cure” after being treated with its PD-L1 antibody. In a Phase IIb clinical trial, 42.9% of chronic hepatitis B patients who received ASC22 (envafolimab) experienced a sustained HBsAg loss. In 2019, Ascletis acquired China rights to develop ASC22 for viral diseases from Suzhou Alphamab. The company has also started trials of the PD-L1 for HIV in China and the US. Ascletis’s initial project was Ganovo, an interferon-free therapy for hepatitis C virus, which was approved for China use in 2018. More details....

Stock Symbol: (HK: 1672)

Share this with colleagues:  

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio Event
Beijing and Digital
November 8-11, 2022
ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
July 27-31, 2022